Last reviewed · How we verify
Tailored antithrombotic strategy
Tailored antithrombotic strategy is a Small molecule drug developed by Duk-Woo Park, MD. It is currently FDA-approved for Thrombotic disease prevention and treatment (various indications including atrial fibrillation, venous thromboembolism, acute coronary syndrome).
A personalized anticoagulation approach that tailors antithrombotic therapy selection and dosing based on individual patient characteristics, biomarkers, and clinical risk factors.
Researchers are studying a tailored antithrombotic strategy, known as CLOT-LESS, which aims to reduce antithrombotic medication in patients who have undergone left atrial appendage closure for stroke prevention. The strategy involves using medications such as apixaban and standard-dose DOACs, which are oligosaccharide-based anticoagulants like fondaparinux.
At a glance
| Generic name | Tailored antithrombotic strategy |
|---|---|
| Sponsor | Duk-Woo Park, MD |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Tailored antithrombotic strategy represents a precision medicine approach to thrombotic disease management, where antithrombotic agents (anticoagulants, antiplatelet drugs, or combinations) are selected and optimized based on patient-specific factors including genetic polymorphisms, renal function, drug interactions, bleeding and clotting risk scores, and comorbidities. This individualized strategy aims to maximize efficacy while minimizing adverse events compared to one-size-fits-all dosing protocols.
Approved indications
- Thrombotic disease prevention and treatment (various indications including atrial fibrillation, venous thromboembolism, acute coronary syndrome)
Common side effects
- Bleeding
- Thrombotic events
Key clinical trials
- Improve Medication Adherence Among Stroke Survivors in Rural Kentucky (NA)
- TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI (PHASE4)
- Transform CV Risk in Diabetes (NA)
- Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial Appendage Occlusion (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tailored antithrombotic strategy CI brief — competitive landscape report
- Tailored antithrombotic strategy updates RSS · CI watch RSS
- Duk-Woo Park, MD portfolio CI
Frequently asked questions about Tailored antithrombotic strategy
What is Tailored antithrombotic strategy?
How does Tailored antithrombotic strategy work?
What is Tailored antithrombotic strategy used for?
Who makes Tailored antithrombotic strategy?
What development phase is Tailored antithrombotic strategy in?
What are the side effects of Tailored antithrombotic strategy?
Related
- Manufacturer: Duk-Woo Park, MD — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Thrombotic disease prevention and treatment (various indications including atrial fibrillation, venous thromboembolism, acute coronary syndrome)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing